Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1989 Jun 3;298(6686):1483–1486. doi: 10.1136/bmj.298.6686.1483

Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme.

E M Smith 1, F W Anthony 1, S C Gadd 1, G M Masson 1
PMCID: PMC1836668  PMID: 2503080

Abstract

OBJECTIVE--To evaluate the effect of support with human chorionic gonadotrophin in the luteal phase in women taking part in an in vitro fertilisation programme after buserelin and human menopausal gonadotrophin were used to hyperstimulate their ovaries. DESIGN--Controlled group comparison. SETTING--Outpatient department of a private hospital. PATIENTS--115 Women with indications for in vitro fertilisation, all of whom had at least one embryo transferred. INTERVENTIONS--After suppression of the pituitary with buserelin the ovaries of all the women were stimulated with human menopausal gonadotrophin on day 4 of the luteal phase. Human chorionic gonadotrophin (10,000 IU) was given to induce ovulation, and oocytes were recovered 34 hours later. Embryos were transferred 46 to 48 hours after insemination. Women who had received the 10,000 IU of human chorionic gonadotrophin on a date that was an uneven number (n = 61) were allocated to receive support doses of 2500 IU human chorionic gonadotrophin three and six days after that date. The remaining 54 women did not receive hormonal support. END POINT--Determination of the rates of pregnancy. MEASUREMENTS and main results--Support with human chorionic gonadotrophin did not significantly alter the progesterone or oestradiol concentrations in the early or mid-luteal phase. The mean (range) progesterone concentrations in the late luteal phase in women who did not become pregnant were, however, significantly higher in those who received support (16(9-110) nmol/l nu 8(4-46) nmol/l), and the luteal phase was significantly longer in this group (14 days nu 12 days). The rate of pregnancy was significantly higher in the women who received support than in those who did not (25/61 nu 8/54). CONCLUSIONS--When buserelin and human menopausal gonadotrophin are used to hyperstimulate ovaries support with human chorionic gonadotrophin in the luteal phase has a beneficial effect on in vitro fertilisation.

Full text

PDF
1483

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayly C. M., McBain J. C., Clarke G. A., Gronow M. J., Johnston W. I., Martin M. J., Speirs A. L. Ovarian stimulation regimens in an in vitro fertilization program: a comparative analysis. Ann N Y Acad Sci. 1985;442:123–127. doi: 10.1111/j.1749-6632.1985.tb37512.x. [DOI] [PubMed] [Google Scholar]
  2. Buvat J., Marcolin G., Herbaut J. C., Dehaene J. L., Verbecq P., Fourlinnie J. C. A randomized trial of human chorionic gonadotropin support following in vitro fertilization and embryo transfer. Fertil Steril. 1988 Mar;49(3):458–461. doi: 10.1016/s0015-0282(16)59773-8. [DOI] [PubMed] [Google Scholar]
  3. Cedard L., Guichard A., Janssens Y., Tanguy G., Boyer P., Zorn J. R. Progesterone and estradiol in saliva after in vitro fertilization and embryo transfer. Fertil Steril. 1987 Feb;47(2):278–283. doi: 10.1016/s0015-0282(16)50006-5. [DOI] [PubMed] [Google Scholar]
  4. Csapo A. I., Pulkkinen M. O., Ruttner B., Sauvage J. P., Wiest W. G. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. Am J Obstet Gynecol. 1972 Apr 15;112(8):1061–1067. doi: 10.1016/0002-9378(72)90181-0. [DOI] [PubMed] [Google Scholar]
  5. Fleming R., Coutts J. R. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression. Fertil Steril. 1986 Feb;45(2):226–230. doi: 10.1016/s0015-0282(16)49159-4. [DOI] [PubMed] [Google Scholar]
  6. Gidley-Baird A. A., O'Neill C., Sinosich M. J., Porter R. N., Pike I. L., Saunders D. M. Failure of implantation in human in vitro fertilization and embryo transfer patients: the effects of altered progesterone/estrogen ratios in humans and mice. Fertil Steril. 1986 Jan;45(1):69–74. doi: 10.1016/s0015-0282(16)49099-0. [DOI] [PubMed] [Google Scholar]
  7. Huang K. E., Muechler E. K., Schwarz K. R., Goggin M., Graham M. C. Serum progesterone levels in women treated with human menopausal gonadotropin and human chorionic gonadotropin for in vitro fertilization. Fertil Steril. 1986 Nov;46(5):903–906. doi: 10.1016/s0015-0282(16)49832-8. [DOI] [PubMed] [Google Scholar]
  8. Jones H. W., Jr, Acosta A. A., Andrews M. C., Garcia J. E., Jones G. S., Mayer J., McDowell J. S., Rosenwaks Z., Sandow B. A., Veeck L. L. Three years of in vitro fertilization at Norfolk. Fertil Steril. 1984 Dec;42(6):826–834. doi: 10.1016/s0015-0282(16)48251-8. [DOI] [PubMed] [Google Scholar]
  9. Mahadevan M. M., Leader A., Taylor P. J. Effects of low-dose human chorionic gonadotropin on corpus luteum function after embryo transfer. J In Vitro Fert Embryo Transf. 1985 Dec;2(4):190–194. doi: 10.1007/BF01201796. [DOI] [PubMed] [Google Scholar]
  10. Muasher S., Acosta A. A., Garcia J. E., Jones G. S., Jones H. W., Jr Luteal phase serum estradiol and progesterone in in vitro fertilization. Fertil Steril. 1984 Jun;41(6):838–843. doi: 10.1016/s0015-0282(16)47895-7. [DOI] [PubMed] [Google Scholar]
  11. Neveu S., Hedon B., Bringer J., Chinchole J. M., Arnal F., Humeau C., Cristol P., Viala J. L. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril. 1987 Apr;47(4):639–643. doi: 10.1016/s0015-0282(16)59115-8. [DOI] [PubMed] [Google Scholar]
  12. O'Neill C., Pike I. L., Porter R. N., Gidley-Baird A. A., Sinosich M. J., Saunders D. M. Maternal recognition of pregnancy prior to implantation: methods for monitoring embryonic viability in vitro and in vivo. Ann N Y Acad Sci. 1985;442:429–439. doi: 10.1111/j.1749-6632.1985.tb37550.x. [DOI] [PubMed] [Google Scholar]
  13. Quigley M. M. Selection of agents for enhanced follicular recruitment in an in vitro fertilization and embryo replacement treatment program. Ann N Y Acad Sci. 1985;442:96–111. doi: 10.1111/j.1749-6632.1985.tb37509.x. [DOI] [PubMed] [Google Scholar]
  14. Russell J. B., Polan M. L., DeCherney A. H. The use of pure follicle-stimulating hormone for ovulation induction in normal ovulatory women in an in vitro fertilization program. Fertil Steril. 1986 Jun;45(6):829–833. doi: 10.1016/s0015-0282(16)49401-x. [DOI] [PubMed] [Google Scholar]
  15. Rutherford A. J., Subak-Sharpe R. J., Dawson K. J., Margara R. A., Franks S., Winston R. M. Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone releasing hormone. Br Med J (Clin Res Ed) 1988 Jun 25;296(6639):1765–1768. doi: 10.1136/bmj.296.6639.1765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sandow J., Engelbart K., von Rechenberg W. The different mechanisms for suppression of pituitary and testicular function. Med Biol. 1986;63(5-6):192–200. [PubMed] [Google Scholar]
  17. Serafini P., Stone B., Kerin J., Batzofin J., Quinn P., Marrs R. P. An alternate approach to controlled ovarian hyperstimulation in "poor responders": pretreatment with a gonadotropin-releasing hormone analog. Fertil Steril. 1988 Jan;49(1):90–95. doi: 10.1016/s0015-0282(16)59655-1. [DOI] [PubMed] [Google Scholar]
  18. Smitz J., Devroey P., Camus M., Deschacht J., Khan I., Staessen C., Van Waesberghe L., Wisanto A., Van Steirteghem A. C. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Hum Reprod. 1988 Jul;3(5):585–590. doi: 10.1093/oxfordjournals.humrep.a136750. [DOI] [PubMed] [Google Scholar]
  19. Trounson A., Howlett D., Rogers P., Hoppen H. O. The effect of progesterone supplementation around the time of oocyte recovery in patients superovulated for in vitro fertilization. Fertil Steril. 1986 Apr;45(4):532–535. doi: 10.1016/s0015-0282(16)49283-6. [DOI] [PubMed] [Google Scholar]
  20. Van Steirteghem A. C., Smitz J., Camus M., Van Waesberghe L., Deschacht J., Khan I., Staessen C., Wisanto A., Bourgain C., Devroey P. The luteal phase after in-vitro fertilization and related procedures. Hum Reprod. 1988 Feb;3(2):161–164. doi: 10.1093/oxfordjournals.humrep.a136667. [DOI] [PubMed] [Google Scholar]
  21. Vargyas J., Kletzky O., Marrs R. P. The effect of laparoscopic follicular aspiration on ovarian steroidogenesis during the early preimplantation period. Fertil Steril. 1986 Feb;45(2):221–225. doi: 10.1016/s0015-0282(16)49158-2. [DOI] [PubMed] [Google Scholar]
  22. Zarutskie P. W., Kuzan F. B., Dixon L., Soules M. R. Endocrine changes in the late-follicular and postovulatory intervals as determinants of the in vitro fertilization pregnancy rate. Fertil Steril. 1987 Jan;47(1):137–143. doi: 10.1016/s0015-0282(16)49949-8. [DOI] [PubMed] [Google Scholar]
  23. Zorn J. R., Barata M., Brami C., Epelboin S., Nathan C., Papageorgiou G., Quantin P., Rolet F., Savale M., Boyer P. Ovarian stimulation for in-vitro fertilization combining administration of gonadotrophins and blockade of the pituitary with D-Trp6-LHRH microcapsules: pilot studies with two protocols. Hum Reprod. 1988 Feb;3(2):235–239. doi: 10.1093/oxfordjournals.humrep.a136684. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES